Compare Freshworks Inc (FRSH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Freshworks Inc trades at $11.81 (market cap $3.31B), while Vertex Pharmaceuticals Incorporated trades at $528 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 40.6× Freshworks Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| FRSH | VRTX | |
|---|---|---|
Market Cap | $3.31B | $134.25B |
Sector | Technology | Health |
52-Week High | $13.97 | $529.65 |
52-Week Low | $6.88 | $376.62 |
Enterprise Value | $2.68B | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
